Drug Trial Radar · NCT03755700
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
Last checked: Nov 19, 2026Latest source record: Nov 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Nov 1, 2018
Primary completion
Dec 31, 2019
Study completion Dec 31, 2019
Sponsor
- Lead sponsor
- Rajaie Cardiovascular Medical and Research CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In a double-blinded randomized clinical trial, all patients undergoing coronary artery catheterization who will met our criteria, will be enrolled into three groups to receive either, vitamin e, n-acetylcysteine, or placebo. The aim of study will be to compare the superiority of vitamin e over n-acetylcysteine for the prevention of contrast-induced acute kidney injury (CIAKI).
Conditions
- Coronary Artery Disease
- Coronary Artery Angiography
- Coronary Catheterization
- Contrast-induced Nephropathy
- Stable Angina
- Acute Coronary Syndrome
Interventions
Vitamin EDrug
As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
N-acetyl cysteineDrug
As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
Placebo oral capsuleDrug
The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
PlacebosDrug
The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
Normal Saline Flush, 0.9% Injectable SolutionDrug
Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Contrast-induced acute kidney injuryTime frame: 48 to 72 hours after coronary catheterization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rajaie cardiovascular medical and research center
Tehran, Iran · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.